Stress, Approach

Here, we must stress the very problem that the success of these approaches in the past few years. Clinical studies have shown that it is possible, in the course of the disease by two categories of drugs currently approved, or at least change in some countries: in the beta interferons and acetate glatiramer. We now know that this treatment is effective in part, is no longer justified, morally, to provide a large scale and over long periods of placebo-controlled clinical studies so far have been necessary to shed light on the effectiveness of new drugs.

While it may be of shorter duration studies are justified morally, but will not be useful to study chronic disease such as MS. Another strategy would be to compare the new therapy to treat the list, but such a study would provide results much more difficult to interpret and will be more expensive than the trials and placebo-controlled. Therefore, we must develop a new approach to clinical trials, and this is exactly the goal of international cooperation, carried out under the auspices of the International Federation of Multiple Sclerosis.